Genomic Exploration of Essential Hypertension in African-Brazilian Quilombo Populations: A Comprehensive Approach with Pedigree Analysis and Family-Based Association Studies - Borges, Vinícius Magalhães; Horimoto, Andrea R.V.R.; Wijsman, Ellen Marie; Kimura, Lilian; Nunes, Kelly; Nato, Alejandro Q.; Mingroni-Netto, Regina Célia (medRxiv, 2024)
Background: Essential Hypertension (EH) is a global health issue, responsible for approximately 9.4 million deaths annually. Its prevalence varies by region, with genetic factors contributing 30-60% to blood pressure variation. Despite extensive research, the genetic complexity of EH remains largely unexplained. This study aimed to investigate the genetic basis of EH in African-derived individuals from partially isolated quilombo remnant populations in Vale do Ribeira (SP-Brazil). Methods: Samples from 431 individuals (167 affected, 261 unaffected, 3 with unknown phenotype) were genotyped using a 650k SNP array. Global ancestry proportions were estimated at 47% African, 36% European, and 16% Native American. Additional data from 673 individuals were used to construct six pedigrees. Pedigrees were pruned, and three non-overlapping marker subpanels were created. We phased haplotypes and performed local ancestry analysis to account for admixture. We then conducted genome-wide linkage analysis (GWLA) and performed fine-mapping through family-based association studies (FBAS) on imputed data and through EH-related genes investigation. Results: Linkage analysis identified 22 ROIs with LOD scores ranging from 1.45 to 3.03, encompassing 2363 genes. Fine-mapping identified 60 EH-related candidate genes and 118 suggestive or significant variants (FBAS). Among these, 14 genes, including PHGDH, S100A10, MFN2, and RYR2, were strongly associated with hypertension and harbors 29 SNPs. Conclusions: Through a complementary approach — combining admixture-adjusted genome-wide linkage analysis based on Markov chain Monte Carlo (MCMC) methods, association studies on imputed data, and in silico investigations — genetic regions, variants, and candidate genes were identified, offering insights into the genetic etiology of EH in quilombo remnant populations.Competing Interest StatementThe authors have declared no competing interest.Funding StatementWe acknowledge funding from CEPID-FAPESP (Research Center on the Human Genome and Stem Cells, grants 1998/14254-2 and 2013/08028-1, and FAPESP/INCT-CNPq 2014/50931-3). This research also received support from grant FAPESP 2012/18010-0, titled Balancing selection in the human genome: detection, causes, and consequences. Additionally, we are grateful to CAPES for the sandwich Ph.D. fellowship #88887.371219/2019-00 and CNPq for the Ph.D. fellowship #142193/2017-8. We also acknowledge funding from the Marshall University Joan C. Edwards School of Medicine, WV-INBRE grant (NIH P20GM103434), Bench-to-Bedside Pilot grant (Nato) under the West Virginia Clinical and Translational Science Institute (WV-CTSI) grant (NIH 5U54GM104942), and Nato startup fund.Author DeclarationsI confirm all relevant ethical guidelines have been followed, and any necessary IRB and/or ethics committee approvals have been obtained.YesThe details of the IRB/oversight body that provided approval or exemption for the research described are given below:Ethics committee/IRB of University of Sao Paulo (Brazil)/Institute of Biomedical Sciences gave ethical approval for this work under the protocol number 111/2001. Ethics committee/IRB of University of Sao Paulo (Brazil)/Institute of Biosciences gave ethical approval for this work under the protocol number 012/2004 and 034/2005.I confirm that all necessary patient/participant consent has been obtained and the appropriate institutional forms have been archived, and that any patient/participant/sample identifiers included were not known to anyone (e.g., hospital staff, patients or participants themselves) outside the research group so cannot be used to identify individuals.YesI understand that all clinical trials and any other prospective interventional studies must be registered with an ICMJE-approved registry, such as ClinicalTrials.gov. I confirm that any such study reported in the manuscript has been registered and the trial registration ID is provided (note: if posting a prospective study registered retrospectively, please provide a statement in the trial ID field explaining why the study was not registered in advance).YesI have followed all appropriate research reporting guidelines, such as any relevant EQUATOR Network research reporting checklist(s) and other pertinent material, if applicable.YesAll data produced in the present study are available upon reasonable request to the authors. https://livemarshall-my.sharepoint.com/:b:/g/personal/magalhaesbor_marshall_edu/EfnaW0V_-aJPjyxSiTESfpkBXlK3cfPUBnFGL2KTiNLOQg?e=fbhHuz